Steven M Kornblau

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients
    P P Ruvolo
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 25:1711-7. 2011
  2. doi request reprint Use of reverse phase protein microarrays to study protein expression in leukemia: technical and methodological lessons learned
    Steven M Kornblau
    Department of Stem Cell Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Methods Mol Biol 785:141-55. 2011
  3. pmc Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia
    Steven M Kornblau
    Departments of Stem Cell Transplantation and Cellular Therapy and Bioinformatics and Computational Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Clin Cancer Res 16:1865-74. 2010
  4. ncbi request reprint Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia
    Steven M Kornblau
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:4251-61. 2010
  5. pmc Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia
    Steven M Kornblau
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 118:5604-12. 2011
  6. ncbi request reprint Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
  7. pmc Functional proteomic profiling of AML predicts response and survival
    Steven M Kornblau
    Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:154-64. 2009
  8. pmc Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML
    Bing Z Carter
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:173-80. 2012
  9. pmc Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells
    Steven M Kornblau
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e78453. 2013
  10. pmc Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
    Zhihong Zeng
    Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:2679-89. 2012

Detail Information

Publications44

  1. pmc Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients
    P P Ruvolo
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 25:1711-7. 2011
    ..These findings suggest that decreased B55α expression in AML is at least partially responsible for increased AKT signaling in AML and suggests that therapeutic targeting of PP2A could counteract this...
  2. doi request reprint Use of reverse phase protein microarrays to study protein expression in leukemia: technical and methodological lessons learned
    Steven M Kornblau
    Department of Stem Cell Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Methods Mol Biol 785:141-55. 2011
    ..The choice of the correct "normal" control is important for comparing diseased to "normal" expression. Various means of normalizing the data are discussed...
  3. pmc Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia
    Steven M Kornblau
    Departments of Stem Cell Transplantation and Cellular Therapy and Bioinformatics and Computational Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Clin Cancer Res 16:1865-74. 2010
    ..This study evaluated the level of expression and the prognostic relevance of total and phosphorylated FOXO3A protein in AML...
  4. ncbi request reprint Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia
    Steven M Kornblau
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:4251-61. 2010
    ..In conclusion, C&Ckine expression in AML and MDS differs from normal, is similar with one another, and forms recurrent patterns of expression with prognostic relevance...
  5. pmc Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia
    Steven M Kornblau
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 118:5604-12. 2011
    ..FLI1 expression is frequently abnormal and prognostically adverse in AML. FLI1 and/or its response genes may be therapeutically targetable to interfere with AML cell biology...
  6. ncbi request reprint Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  7. pmc Functional proteomic profiling of AML predicts response and survival
    Steven M Kornblau
    Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:154-64. 2009
    ..Confirmation in independent studies may also provide pathophysiologic insights facilitating triage of patients to emerging targeted therapies...
  8. pmc Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML
    Bing Z Carter
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:173-80. 2012
    ..These results suggest that survivin is a prognostic biomarker in AML and that survivin, which is overexpressed in AML stem/progenitor cells, remains a potentially important target for leukemia therapy...
  9. pmc Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells
    Steven M Kornblau
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e78453. 2013
    ..1(SP1), P27, Mcl1, HIF1α, cMET, P53, Yap, and phospho-Stats 1, 5 and 6. Protein expression and activation in LSC differs markedly from other blast populations suggesting that studies of AML biology should be performed in LSC...
  10. pmc Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
    Zhihong Zeng
    Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:2679-89. 2012
    ..Our findings indicate that disrupting mTOR/AKT signaling with a selective mTOR kinase inhibitor can effectively target leukemic cells within the BM microenvironment...
  11. pmc Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML
    Bing Z Carter
    Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 117:780-7. 2011
    ..These results suggest that ARC expression levels are highly prognostic in AML and that ARC is a potential therapeutic target in AML...
  12. ncbi request reprint Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2177-87. 2002
    ..We identified pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival...
  13. pmc Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents
    Bing Z Carter
    Affiliations of authors Section of Molecular Hematology and Therapy, Department of Leukemia BZC, PYM, DHM, YS, YQ, hm, ROJ, TM, SMK, MA and Department of Bioinformatics and Computational Biology HY, Krc, University of Texas M D Anderson Cancer Center, Houston, TX Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ JMB, RT
    J Natl Cancer Inst 106:djt440. 2014
    ....
  14. pmc Overexpression of ZNF342 by juxtaposition with MPO promoter/enhancer in the novel translocation t(17;19)(q23;q13.32) in pediatric acute myeloid leukemia and analysis of ZNF342 expression in leukemia
    Kathryn S Poland
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
    Genes Chromosomes Cancer 48:480-9. 2009
    ..0016) and AML subtype M7 (P = 0.0002). Thus, overexpression of ZNF342 by translocation or other mechanisms contributes to leukemia biology in multiple hematopoietic compartments...
  15. ncbi request reprint Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
    Paolo Strati
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 122:734-7. 2013
    ..Compared with other patients in the study, LTRs had lower baseline plasma levels of β-2-microglobulin, were more likely to have trisomy 12, and less likely to have deletion 17p...
  16. ncbi request reprint Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells"
    Steven M Kornblau
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cell Cycle 5:2769-77. 2006
    ..Analysis of SV cells may be more informative than analysis of the bulk population of leukemia cells...
  17. ncbi request reprint Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
    Ahmed Aribi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:1355-9. 2007
    ..Arsenic trioxide (ATO) is an effective agent for the salvage of patients with recurrent APL, and gemtuzumab ozogamicin (GO) has shown activity in patients with APL...
  18. pmc Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia
    Sergej Konoplev
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 54:138-44. 2013
    ..All cases of Ph+ AML were negative for ABL1 and other gene mutations. One (20%) patient with CML-BP had ABL1 mutation; no patients had NPM1 mutations. These data suggest that Ph+ AML is distinct from CML-BP...
  19. ncbi request reprint Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
    Raoul Tibes
    Department of Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Mol Cancer Ther 5:2512-21. 2006
    ....
  20. pmc Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines
    Victor A Levin
    Departments of Neuro Oncology, Bioinformatics and Computational Biology, and Blood and Marrow Transplantation, Section of Molecular Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
    J Proteome Res 9:179-91. 2010
    ..Contrawise, gliomas become resistant to apoptosis after 24 h of serum starvation and upregulate transcription activators and polyamines more so than adenocarciomas...
  21. pmc Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide
    Chad C Bjorklund
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 286:11009-20. 2011
    ....
  22. pmc The epigenome of AML stem and progenitor cells
    Jumpei Yamazaki
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Epigenetics 8:92-104. 2013
    ..Our data indicates that histone modifications but not promoter DNA methylation are involved in switches from CSCs to non-CSCs in AML...
  23. pmc Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia
    Mary E Irwin
    Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 8:e70608. 2013
    ..Our results suggest that ErbB signaling is an additional molecular target in Ph(+)ALL and encourage the development of clinical strategies combining ErbB and BCR/ABL kinase inhibitors for this subset of ALL patients...
  24. ncbi request reprint Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias
    Marina Konopleva
    Section of Molecular Hematology and Therapy and Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 3:1249-62. 2004
    ....
  25. ncbi request reprint Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis
    Bing Z Carter
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:4179-86. 2003
    ..This may partially explain the lack of prognostic impact of XIAP and Survivin and may suggest caspase-independent mechanisms of cell death in AML...
  26. pmc Prognostic impact and targeting of CRM1 in acute myeloid leukemia
    Kensuke Kojima
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 121:4166-74. 2013
    ..We propose a novel combinatorial approach for the therapy of AML, aimed at maximal activation of p53-mediated apoptosis by concomitant MDM2 and CRM1 inhibition...
  27. doi request reprint Network analysis of reverse phase protein expression data: characterizing protein signatures in acute myeloid leukemia cytogenetic categories t(8;21) and inv(16)
    Heather York
    Department of Bioengineering, Rice University, Houston, TX, USA
    Proteomics 12:2084-93. 2012
    ..By characterizing unique "protein signatures" through this rapid computational analysis, and placing them in the context of canonical biological networks, we identify signaling pathways distinct to subcategories of AML patients...
  28. pmc Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
    Steven M Kornblau
    Section of Molecular Hematology and Therapy, Unit 448, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:2358-65. 2006
    ..It is thus likely that only combinations of agents that target the multiply activated STPs will be beneficial for patients with AML...
  29. ncbi request reprint The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells
    Peter P Ruvolo
    Division of Molecular Hematology, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Biochim Biophys Acta 1843:1969-77. 2014
    ..In summary, the suppression of B55α activates signaling pathways that could support leukemia cell survival. ..
  30. pmc Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment
    Olga Frolova
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 13:858-70. 2012
    ..Hence, mTOR inhibition or blockade of HIF-1α-mediated signaling may play an important role in chemosensitization of ALL cells under hypoxic conditions of the BM microenvironment...
  31. ncbi request reprint Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia
    Zhihong Zeng
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 66:3737-46. 2006
    ..Taken together, our results show that the simultaneous inhibition of critical prosurvival kinases by KP372-1 leads to mitochondrial dysfunction and apoptosis of AML but not normal hematopoietic progenitor cells...
  32. ncbi request reprint DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia
    Guillermo Garcia-Manero
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2217-24. 2002
    ..Aberrant methylation of promoter-associated CpG islands is an epigenetic oncogenic mechanism. The objective of this study was to define the methylation characteristics of patients with acute lymphocytic leukemia (ALL)...
  33. pmc Notch activation inhibits AML growth and survival: a potential therapeutic approach
    Sankaranarayanan Kannan
    Division of Pediatrics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Exp Med 210:321-37. 2013
    ..In conclusion, we report consistent Notch-mediated growth arrest and apoptosis in human AML, and propose the development of Notch agonists as a potential therapeutic approach in AML...
  34. ncbi request reprint Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24)
    Patrick A Lennon
    School of Health Sciences, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Cancer Genet Cytogenet 177:37-42. 2007
    ..Western blot analysis detected EVI1 in one case analyzed. We conclude that the t(3;8)(q26;q24) results in deregulated EVI1 expression, similar to other balanced or unbalanced chromosomal translocations involving chromosome 3q26...
  35. ncbi request reprint Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
    Xavier C Badoux
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:3489-98. 2011
    ..Lenalidomide therapy was well tolerated and induced durable remissions in this population of elderly, symptomatic patients with CLL. This study was registered at www.clinicaltrials.gov as #NCT00535873...
  36. pmc Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study
    Steven M Kornblau
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Blood 109:2999-3006. 2007
    ..An MTD for PV + Ida-HDAC was not reached. Addition of PV to Ida-HDAC was safe, and the encouraging response rates support conducting further trials evaluating the effect of cholesterol modulation on response in AML...
  37. pmc Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
    Cancer 118:5283-92. 2012
    ..The biologic basis for progression from chronic phase to blastic phase and for regulating the homeostasis of tyrosine kinase inhibitor-resistant CML stem cells is not entirely understood...
  38. pmc Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
    Sally A Hunsucker
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Br J Haematol 152:579-92. 2011
    ..These studies provide a rationale for translation of siltuximab into the clinic in combination with melphalan-based therapies...
  39. pmc Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias
    Bella S Guerrouahen
    Division of Pediatrics, Departments of Leukemia and Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 60611, USA
    Clin Cancer Res 16:1149-58. 2010
    ..Because Src kinases contribute to multiple blood cell functions by triggering a variety of signaling pathways, we hypothesized that their molecular targeting might lead to growth inhibition in acute myeloid leukemia (AML)...
  40. pmc Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes
    Steven M Kornblau
    Department of Blood and Marrow Transplantation, Unit 448, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Exp Hematol 35:842-53. 2007
    ....
  41. ncbi request reprint Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2167-76. 2002
    ..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...
  42. pmc Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy
    Steven M Kornblau
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 16:3721-33. 2010
    ..However, no methods exist to predict with high accuracy at the individual patient level the response to standard AML induction therapy...
  43. pmc Variable slope normalization of reverse phase protein arrays
    E Shannon Neeley
    Department of Statistics, Rice University, Houston, TX, USA
    Bioinformatics 25:1384-9. 2009
    ..When the variability in sample loading is large, these methods are suboptimal because they do not account for the fact that the protein expression for each slide is estimated separately...
  44. ncbi request reprint Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
    Michele Milella
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3461-4. 2002
    ..These findings show that the Bcl-2 and MAPK pathways are relevant molecular targets in AML and that their concurrent inhibition could be developed into a new therapeutic strategy for this disease...